TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ABILIFY MYCITE KIT

ARIPIPRAZOLE
Approved 2017-11-13
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Discontinued
First Approved
2017-11-13
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ARIPIPRAZOLE

ABILIFY MYCITE KIT Approval History

Loading approval history...

What ABILIFY MYCITE KIT Treats

1 FDA approvals

Originally approved for its first indication in 2017 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ABILIFY MYCITE KIT FDA Label Details

Pro

ABILIFY MYCITE KIT Patents & Exclusivity

Latest Patent: Oct 2033

Patents (972 active)

US9268909 Expires Oct 15, 2033
US10517507 Expires Jun 13, 2032
US9320455 Expires Dec 15, 2031
US11229378 Expires Jul 11, 2031
US8547248 Expires Dec 18, 2030
US8258962 Expires Nov 25, 2030
US8961412 Expires Nov 17, 2030
US9941931 Expires Nov 4, 2030
US11464423 Expires Sep 15, 2030
US8114021 Expires Jun 21, 2030
+ 962 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.